Rang & Dale's Pharmacology
- 10th Edition - May 13, 2023
- Authors: James M. Ritter, Rod J. Flower, Graeme Henderson, Yoon Kong Loke, David MacEwan, Emma Robinson, James Fullerton
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 8 7 3 9 6 - 3
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 8 7 3 9 5 - 6
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 7 3 9 8 - 7
Rang and Dale’s Pharmacology is internationally acknowledged as the core textbook for students of pharmacology, and has provided accessible, up-to-date information on drugs and… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteRang and Dale’s Pharmacology is internationally acknowledged as the core textbook for students of pharmacology, and has provided accessible, up-to-date information on drugs and their mechanism of action for more than 30 years.
Now in its tenth edition, it has been updated to include important new drugs such as gene therapies, personalised medicines and the new wave of RNA drugs. However it has not lost any of the elements that have contributed to its popularity, such as color coding and illustrations, making it reader-friendly while comprehensively covering the depth of detail required.
This essential book is recommended as the first-choice undergraduate text for science and medical students and junior doctors and will also be useful for students in other professional disciplines such as pharmacy, veterinary medicine and nursing.
- Comprehensive information on drug mechanisms, basic physiology and biochemistry, and underlying pathophysiology of disease – suitable for students from many disciplines
- Clear figures to aid understanding, including data figures as well as mechanistic diagrams,
- Key points box summaries, clinical boxes and colour-coded chapters help to master difficult concepts
- Emphasis on therapeutic drugs to help apply theory to practice
- Over 150 questions and 12 clinical cases to test your knowledge
- An enhanced eBook version is included with purchase. The eBook allows you to access all the text, figures and references, with the ability to search, customise your content, make notes and highlights, and have content read aloud
- Instructions for online access
- Cover image
- Title page
- Table of Contents
- How to Use
- Copyright
- Video and Case Study Contents
- Inflammation case study
- Cardiovascular case study
- Respiratory case study
- Food and glucose regulation case study
- Neurodegenerative disease case study
- Epilepsy case study
- Cancer case study
- Videos Contents
- Rang & Dale’s Pharmacology Tenth Edition Preface
- Section 1. GENERAL PRINCIPLES
- 1. What is pharmacology?
- What is a Drug?
- Origins and Antecedents
- Pharmacology in the 20th and 21st Centuries
- 2. How drugs act: general principles
- Introduction
- Protein Targets for Drug Binding
- Desensitisation and Tolerance
- Quantitative Aspects of Drug–Receptor Interactions
- The Nature of Drug Effects
- 3. How drugs act: molecular aspects
- Protein Targets for Drug Action
- Receptor Proteins
- Ion Channels as Drug Targets
- Control of Receptor Expression
- Receptors and Disease
- 4. How drugs act: cellular aspects – excitation, contraction and secretion
- Regulation of Intracellular Calcium
- Excitation
- Muscle Contraction
- Release of Chemical Mediators
- Epithelial Ion Transport
- 5. How drugs act: biopharmaceuticals and gene therapy
- INTRODUCTION
- PROTEIN AND PEPTIDE BIOPHARMACEUTICALS
- OLIGONUCLEOTIDES
- GENE THERAPY
- SAFETY AND SOCIETAL ISSUES
- THERAPEUTIC APPLICATIONS
- FUTURE DIRECTIONS
- 6. Cell proliferation, apoptosis, repair and regeneration
- Cell Proliferation
- Angiogenesis
- Apoptosis and Cell Removal
- Pathophysiological Implications
- Therapeutic Prospects
- 7. Cellular mechanisms: host defence
- Introduction
- The Innate Immune Response
- The Adaptive Immune Response
- Systemic Responses in Inflammation
- 8. Method and measurement in pharmacology
- BIOASSAY
- ANIMAL MODELS OF DISEASE
- PHARMACOLOGICAL STUDIES IN HUMANS
- CLINICAL TRIALS
- CLINICAL CONSIDERATION OF BENEFIT AND RISK
- 9. Absorption and distribution of drugs
- Introduction
- Physical Processes Underlying Drug Disposition
- Drug Absorption and Routes of Administration
- Distribution of Drugs in the Body
- Special Drug Delivery Systems
- 10. Drug metabolism and elimination
- INTRODUCTION
- DRUG AND METABOLITE EXCRETION
- 11. Pharmacokinetics
- Introduction: Definition and uses of Pharmacokinetics
- Drug Elimination Expressed as Clearance
- Single-Compartment Model
- More Complicated Kinetic Models
- Population Pharmacokinetics
- Limitations of Pharmacokinetics
- 12. Individual variation, pharmacogenomics and personalised medicine
- Introduction
- Epidemiological Factors and Inter-Individual Variation of Drug Response
- Genetic Variation in Drug Responsiveness
- Therapeutic Drugs and Clinically Available Pharmacogenomic Tests
- Conclusions
- Section 2. CHEMICAL MEDIATORS
- 13. Chemical mediators and the autonomic nervous system
- Historical Aspects
- The Autonomic Nervous System
- Some General Principles of Chemical Transmission
- Basic Steps in Neurochemical Transmission: Sites of Drug Action
- 14. Cholinergic transmission
- Muscarinic and Nicotinic Actions of Acetylcholine
- Acetylcholine Receptors
- Nicotinic Receptors
- Physiology of Cholinergic Transmission
- Effects of Drugs on Cholinergic Transmission
- 15. Noradrenergic transmission
- Catecholamines
- Classification of Adrenoceptors
- Physiology of Noradrenergic Transmission
- Drugs Acting on Noradrenergic Transmission
- 16. 5-Hydroxytryptamine and the purines
- 5-Hydroxytryptamine
- Clinical Conditions in Which 5-HT Plays a Role
- Purines
- Purinergic Receptors
- The Purinergic System in Health and Disease
- Purines as Neurotransmitters
- Summary
- 17. Local hormones: histamine, lipids, peptides and proteins
- Introduction
- What is a ‘Mediator’?
- Histamine
- Eicosanoids
- Leukotrienes
- Other Important Fatty Acid Derivatives
- Platelet-Activating Factor
- Sphingosine 1-Phosphate
- Protein and Peptide Mediators
- Biosynthesis and Regulation of Peptides
- Bradykinin
- Neuropeptides
- Cytokines
- Proteins and Peptides that Down-Regulate Inflammation
- Concluding Remarks
- 18. Cannabinoids
- Plant-Derived Cannabinoids (‘Phytocannabinoids’) And Their Pharmacological Effects
- Cannabinoid Receptors
- Endocannabinoids
- Synthetic Cannabinoids
- Clinical Applications
- 19. Nitric oxide and related mediators
- Introduction
- Biosynthesis of Nitric Oxide and its Control
- Degradation and Carriage of Nitric Oxide
- Effects of Nitric Oxide
- Therapeutic Aspects
- Clinical Conditions in Which Nitric Oxide May Play a Part
- Related Mediators
- Section 3. DRUGS AFFECTING MAJOR ORGAN SYSTEMS
- 20. The heart
- Introduction
- Physiology of Cardiac Function
- Autonomic Control of the Heart
- Cardiac Natriuretic Peptides
- Ischaemic Heart Disease
- Drugs that Affect Cardiac Function
- 21. The vascular system
- Introduction
- Vascular Structure and Function
- Control of Vascular Smooth Muscle Tone
- Vasoactive Drugs
- Clinical Uses of Vasoactive Drugs
- 22. Atherosclerosis and lipoprotein metabolism
- Introduction
- Atherogenesis
- Lipoprotein Transport
- Prevention of Atheromatous Disease
- Lipid-Lowering Drugs
- Antisense Oligonucleotides
- 23. Haemostasis and thrombosis
- Introduction
- Blood Coagulation
- Drugs that Act on the Coagulation Cascade
- Platelet Adhesion and Activation
- Fibrinolysis (Thrombolysis)
- 24. Haematopoietic system and treatment of anaemia
- Introduction
- The Haematopoietic System
- Types of Anaemia
- Haematinic Agents
- Haematopoietic Growth Factors
- Haemolytic Anaemia
- 25. Anti-inflammatory and immunosuppressant drugs
- Introduction
- Cyclo-Oxygenase Inhibitors
- Antirheumatoid Drugs
- BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS, ANTICYTOKINE DRUGS AND OTHER BIOPHARMACEUTICALS
- Drugs Used in Gout
- Antagonists of Histamine
- Possible Future Developments in Anti-Inflammatory Therapy
- 26. Skin
- Introduction
- Structure of Skin
- Common Diseases of the Skin
- Drugs Acting on Skin
- Principal Drugs Used in Skin Disorders
- Agents Acting by Other Mechanisms
- Concluding Remarks
- 27. The eye
- Introduction
- Special Pharmacokinetic Considerations in the Eye
- Treatment of Inflammation and Infection in the Eye
- Control of Intraocular Pressure and Treatment of Glaucoma
- Ocular Vasculature and Vascular Endothelial Growth Factor Inhibitors
- 28. Respiratory system
- The Physiology of Respiration
- Pulmonary Disease and its Treatment
- 29. The kidney and urinary system
- Introduction
- Outline of Renal Function
- The Structure and Function of the Nephron
- Drugs Acting on the Kidney
- Drugs that Alter the pH of the Urine
- Drugs that Alter the Excretion of Organic Molecules
- Drugs Used in Renal Failure
- Drugs Used in Urinary Tract Disorders
- 30. The gastrointestinal tract
- The Innervation and Hormones of the Gastrointestinal Tract
- Gastric Secretion
- Vomiting
- The Motility of the GI Tract
- Drugs for Chronic Bowel Disease
- Drugs Affecting the Biliary System
- Future Directions
- 31. The control of blood glucose and drug treatment of diabetes mellitus
- Introduction
- Control of Blood Glucose
- Pancreatic Islet Hormones
- Diabetes Mellitus
- 32. Obesity
- Introduction
- Obesity as a Health Problem
- Homeostatic Mechanisms Controlling Energy Balance
- The Pathophysiology of Human Obesity
- Pharmacological Approaches to the Problem of Obesity
- New Approaches to Obesity Therapy
- 33. The pituitary and the adrenal cortex
- The Pituitary Gland
- The Adrenal Cortex
- New Directions in Glucocorticoid Therapy
- 34. The thyroid
- Synthesis, Storage and Secretion of Thyroid Hormones
- Regulation of Thyroid Function
- Actions of the Thyroid Hormones
- Transport and Metabolism of Thyroid Hormones
- Abnormalities of Thyroid Function
- Drugs Used in Diseases of the Thyroid
- 35. The reproductive system
- Introduction
- Endocrine Control of Reproduction
- Drugs Affecting Reproductive Function
- Drugs Used for Contraception
- The Uterus
- Erectile Dysfunction
- 36. Bone metabolism
- Introduction
- Bone Structure and Composition
- Bone Remodelling
- Disorders of Bone
- Drugs Used in Bone Disorders
- Section 4. NERVOUS SYSTEM
- 37. Chemical transmission and drug action in the central nervous system
- Introduction
- Chemical Signalling in the Nervous System
- Targets for Drug Action
- Drug Action in the Central Nervous System
- The Classification of Psychotropic Drugs
- 38. Amino acid transmitters
- Excitatory Amino Acids
- Glutamate
- γ-AMINOBUTYRIC ACID
- Glycine
- Concluding Remarks
- 39. Other transmitters and modulators
- Introduction
- Noradrenaline
- Dopamine
- 5-Hydroxytryptamine
- Acetylcholine
- Purines
- Histamine
- Other CNS Mediators
- A Final Message
- 40. Neurodegenerative diseases
- Protein Misfolding and Aggregation in Chronic Neurodegenerative Diseases
- Mechanisms of Neuronal Death
- Ischaemic Brain Damage
- Dementia
- Parkinson’s Disease
- Essential Tremor
- Huntington’s Disease
- Amyotrophic Lateral Sclerosis
- Spinal Muscular Atrophy
- Multiple Sclerosis
- 41. General anaesthetic agents
- Overview
- Introduction
- Mechanism of Action of Anaesthetic Drugs
- Intravenous Anaesthetic Agents
- Inhalation Anaesthetics
- Individual Inhalation Anaesthetics
- Sedation and Balanced Anaesthesia
- 42. Headache
- Headache
- Types of Headaches
- Drug Therapy for Headache
- Summary
- 43. Analgesic drugs
- Introduction
- Neural Mechanisms of Pain
- Analgesic Drugs
- Chronic Pain
- 44. Local anaesthetics and other drugs affecting sodium channels
- Local Anaesthetics
- Other Drugs That Affect Sodium Channels
- 45. Anxiolytic and hypnotic drugs
- The Nature Of Anxiety And Its Treatment
- Measurement Of Anxiolytic Activity
- Drugs Used To Treat Anxiety
- Delayed Anxiolytic Effect Of Drugs Acting Via Serotonergic Mechanisms
- Drugs Used To Treat Insomnia (Hypnotic Drugs)
- 46. Antiepileptic drugs
- Overview
- Introduction
- The Nature of Epilepsy
- Antiepileptic Drugs
- Muscle Spasm and Muscle Relaxants
- 47. Antipsychotic drugs
- Introduction
- The Nature of Schizophrenia
- Antipsychotic Drugs
- Future Developments
- 48. Antidepressant drugs
- The Nature of Depression
- Theories of Depression
- Antidepressant Drugs
- Clinical Effectiveness of Antidepressant Treatments
- Future Antidepressant Drugs
- Brain Stimulation Therapies
- Drug Treatment of Bipolar Disorder
- 49. Psychoactive drugs
- Introduction
- Psychomotor Stimulants
- Cognition-Enhancing Drugs
- Psychedelic Drugs
- Dissociative Drugs
- Depressants
- Synthetic Cannabinoid Receptor Agonists
- 50. Drug use and addiction
- Drug Use
- Harm Reduction
- Section 5. DRUGS USED FOR THE TREATMENT OF INFECTIONS AND CANCER
- 51. Basic principles of antimicrobial chemotherapy
- Background
- The Molecular Basis of Chemotherapy
- Resistance to Antibacterial Drugs
- Current Status of Antibiotic Resistance in Bacteria
- 52. Antibacterial drugs
- INTRODUCTION
- ANTIBACTERIAL AGENTS THAT INTERFERE WITH FOLATE SYNTHESIS OR ACTION
- β-LACTAM ANTIBIOTICS AND OTHER AGENTS THAT INTERFERE WITH BACTERIAL WALL OR MEMBRANE SYNTHESIS
- ANTIMICROBIAL AGENTS AFFECTING BACTERIAL PROTEIN SYNTHESIS
- ANTIMICROBIAL AGENTS AFFECTING TOPOISOMERASE
- MISCELLANEOUS ANTIBACTERIAL AGENTS
- ANTIMYCOBACTERIAL AGENTS
- PROSPECTS FOR NEW ANTIBACTERIAL DRUGS
- 53. Antiviral drugs
- Background Information About Viruses
- The Host–Virus Interaction
- HIV and AIDS
- COVID-19
- Antiviral Drugs
- Combination Therapy For HIV
- COVID-19 Pharmacotherapy
- Prospects for New Antiviral Drugs
- 54. Antifungal drugs
- Fungi and Fungal Infections
- Drugs Used to Treat Fungal Infections
- Future Developments
- 55. Antiprotozoal drugs
- Background
- Host–Parasite Interactions
- Malaria and Antimalarial Drugs
- Amoebiasis and Amoebicidal Drugs
- Trypanosomiasis and Trypanocidal Drugs
- Other Protozoal Infections and Drugs Used to Treat Them
- Future Developments
- 56. Antihelminthic drugs
- Helminth Infections
- Antihelminthic Drugs
- Resistance to Antihelminthic Drugs
- Vaccines and Other Novel Approaches
- 57. Anticancer drugs
- Introduction
- The Pathogenesis of Cancer
- General Principles of Cytotoxic Anticancer Drugs
- Anticancer Drugs
- Future Developments
- Section 6. SPECIAL TOPICS
- 58. Harmful effects of drugs
- Introduction
- Classification of Adverse Drug Reactions
- Drug Toxicity
- Immunological Reactions to Drugs
- 59. Lifestyle and drugs in sport
- What are Lifestyle Drugs?
- Classification of Lifestyle Drugs
- Cognitive Enhancers
- Drugs and Sex
- Drugs in Sport
- Regulatory, Societal and Ethical Issues
- Conclusion
- 60. Drug discovery and development
- Drug Discovery: Background
- The Stages of a Project
- Biopharmaceuticals
- Commercial Aspects
- Future Prospects
- A Final Word
- Index
- No. of pages: 872
- Language: English
- Edition: 10
- Published: May 13, 2023
- Imprint: Elsevier
- Paperback ISBN: 9780323873963
- Paperback ISBN: 9780323873956
- eBook ISBN: 9780323873987
JR
James M. Ritter
Affiliations and expertise
Emeritus Professor of Clinical Pharmacology, King’s College London, and Medical Research Director, Quintiles, London, UKRF
Rod J. Flower
Affiliations and expertise
Professor, Biochemical Pharmacology, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London , London, UKGH
Graeme Henderson
Affiliations and expertise
Professor of Pharmacology, University of Bristol, Bristol, UKYL
Yoon Kong Loke
Affiliations and expertise
Senior Lecturer in Clinical Pharmacology, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UKDM
David MacEwan
Affiliations and expertise
Professor of Molecular Pharmacology/Toxicology & Head of Department, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United KingdomER
Emma Robinson
Professor of Psychopharmacology, University of Bristol, Bristol, UK
Affiliations and expertise
Professor of Psychopharmacology, University of Bristol, Bristol, UKJF
James Fullerton
Associate Professor of Clinical Therapeutics and Honorary Consultant in Acute General Medicine and Clinical Pharmacology, University of Oxford, Oxford, United Kingdom
Affiliations and expertise
Associate Professor of Clinical Therapeutics and Honorary Consultant in Acute General Medicine and Clinical Pharmacology, University of Oxford, Oxford, United Kingdom